litlas
Log inCreate account

Stephen J. Schuster

Active 1993–2026

Also published as
Stephen J Schuster
180
Papers
29,799
Citations
77
h-index
166
i10-index

Citations

Citations per year for Stephen J. Schuster1992: 1 citations1993: 2 citations1994: 2 citations1999: 2 citations2000: 1 citations2001: 5 citations2002: 4 citations2003: 10 citations2004: 24 citations2005: 39 citations2006: 44 citations2007: 42 citations2008: 32 citations2009: 30 citations2010: 52 citations2011: 52 citations2012: 36 citations2013: 51 citations2014: 55 citations2015: 227 citations2016: 247 citations2017: 329 citations2018: 356 citations2019: 1,070 citations2020: 1,505 citations2021: 1,485 citations2022: 1,390 citations2023: 1,232 citations2024: 2,110 citations2025: 1,096 citations2026: 32 citations1995–1998: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 4,126 citing papers, 30.4% of this breakdownChina: 1,371 citing papers, 10.1% of this breakdownGermany: 870 citing papers, 6.4% of this breakdownUnited Kingdom: 743 citing papers, 5.5% of this breakdownItaly: 680 citing papers, 5% of this breakdownFrance: 643 citing papers, 4.7% of this breakdownSpain: 487 citing papers, 3.6% of this breakdownCanada: 415 citing papers, 3.1% of this breakdownAustralia: 403 citing papers, 3% of this breakdownSwitzerland: 375 citing papers, 2.8% of this breakdownJapan: 317 citing papers, 2.3% of this breakdownNetherlands: 317 citing papers, 2.3% of this breakdown
0%30.4%Other 20.8%

Institutions

Fields

  • Medicine86.3%
  • Biochemistry, Genetics and Molecular Biology6.9%
  • Immunology and Microbiology5.5%
  • Engineering0.4%
  • Neuroscience0.1%
  • Chemistry0.1%
  • Other0.7%

Topics

  • CAR-T cell therapy research18%
  • Lymphoma Diagnosis and Treatment9.4%
  • Cancer Immunotherapy and Biomarkers6.4%
  • Chronic Lymphocytic Leukemia Research5.6%
  • Immune Cell Function and Interaction5.2%
  • Virus-based gene therapy research3.7%
  • Other51.7%

Coauthors

All papers

Open in search
  1. Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma

    Authors: Stephen J. Schuster, Michael Bishop, Constantine S. Tam, Edmund K. Waller, Peter Borchmann, Joseph P. McGuirk, Ulrich Jäger, Samantha Jaglowski, Charalambos Andreadis, Jason R. Westin, Isabelle Fleury, Veronika Bachanová, S.R. Foley, P. Joy Ho, Stephan Mielke, John Magenau, Harald Holte, Serafino Pantano, Lida Pacaud, Rakesh Awasthi, Jufen Chu, Özlem Anak, Gilles Salles, Richard T. Maziarz - New England Journal of Medicine 2018 cited by 4,044

  2. Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas

    Authors: Stephen J. Schuster, Jakub Svoboda, Elise A. Chong, Sunita D. Nasta, Anthony R. Mato, Özlem Anak, Jennifer L. Brogdon, Iulian Pruteanu-Malinici, Vijay Bhoj, Daniel J. Landsburg, Mariusz A. Wasik, Bruce L. Levine, Simon F. Lacey, J. Joseph Melenhorst, David L. Porter, Carl H. June - New England Journal of Medicine 2017 cited by 1,854

  3. Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial

    Authors: Nathan Fowler, Michael Dickinson, Martin Dreyling, Joaquín Martínez‐López, Arne Kolstad, Jason Butler, Monalisa Ghosh, Leslie Popplewell, Julio C. Chávez, Emmanuel Bachy, Koji Kato, Hideo Harigae, Marie José Kersten, Charalambos Andreadis, Peter A. Riedell, P. Joy Ho, José Antonio Pérez‐Simón, Andy I. Chen, Loretta J. Nastoupil, Bastian von Tresckow, Andrés J.M. Ferreri, Takanori Teshima, Piers Patten, Joseph P. McGuirk, Andreas Petzer, Fritz Offner, Andreas Viardot, Pier Luigi Zinzani, Ram Malladi, Aiesha Zia, Rakesh Awasthi, Aisha Masood, Oezlem Anak, Stephen J. Schuster, Catherine Thiéblemont - Nature Medicine 2021 cited by 527

  4. Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study

    Authors: Lihua E. Budde, Laurie H. Sehn, Matthew J. Matasar, Stephen J. Schuster, Sarit Assouline, Pratyush Giri, John Kuruvilla, Miguel Canales, Sascha Dietrich, Keith Fay, Matthew Ku, Loretta J. Nastoupil, Chan Y. Cheah, Michael C. Wei, Shen Yin, Chi‐Chung Li, Huang Huang, Antonia Kwan, Elicia Penuel, Nancy L. Bartlett - The Lancet Oncology 2022 cited by 436

  5. Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study

    Authors: Stephen J. Schuster, Constantine S. Tam, Peter Borchmann, Nina Worel, Joseph P. McGuirk, Harald Holte, Edmund K. Waller, Samantha Jaglowski, Michael Bishop, Lloyd E. Damon, S.R. Foley, Jason R. Westin, Isabelle Fleury, P. Joy Ho, Stephan Mielke, Takanori Teshima, Murali Janakiram, Jing-Mei Hsu, Koji Izutsu, Marie José Kersten, Monalisa Ghosh, Nina D. Wagner‐Johnston, Koji Kato, Paolo Corradini, Marcela Martínez-Prieto, Xia Han, Ranjan Tiwari, Gilles Salles, Richard T. Maziarz - The Lancet Oncology 2021 cited by 561

  6. T cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapy

    Authors: Guido Ghilardi, Joseph A. Fraietta, James N. Gerson, Vivianna M. Van Deerlin, Jennifer J.D. Morrissette, Gabriel C. Caponetti, Luca Paruzzo, Jaryse Harris, Elise A. Chong, Sandra P. Susanibar-Adaniya, Jakub Svoboda, Sunita D. Nasta, Ositadimma Ugwuanyi, Daniel J. Landsburg, Eugenio Fardella, Adam Waxman, Emeline R. Chong, Vrutti Patel, Raymone Pajarillo, Irina Kulikovskaya, David Lieberman, Adam D. Cohen, Bruce L. Levine, Edward A. Stadtmauer, Noelle V. Frey, Dan T. Vogl, Elizabeth O. Hexner, Stefan K. Barta, David L. Porter, Alfred L. Garfall, Stephen J. Schuster, Carl H. June, Marco Ruella - Nature Medicine 2024 cited by 256

  7. PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma

    Authors: Stephen M. Ansell, Alexander M. Lesokhin, Ivan Borrello, Ahmad Halwani, Emma C. Scott, Martin Gutierrez, Stephen J. Schuster, Michael Millenson, Deepika Cattry, Gordon J. Freeman, Scott J. Rodig, Bjoern Chapuy, Azra H. Ligon, Lili Zhu, Joseph F. Grosso, Su Young Kim, John M. Timmerman, Margaret A. Shipp, Philippe Armand - New England Journal of Medicine 2014 cited by 3,547

  8. An NK-like CAR T cell transition in CAR T cell dysfunction

    Authors: Charly R. Good, M. Ángela Aznar, Shunichiro Kuramitsu, Parisa Samareh, Sangya Agarwal, Greg Donahue, Kenichi Ishiyama, Nils Wellhausen, Austin K. Rennels, Yujie Ma, Lifeng Tian, Sònia Guedan, Katherine A. Alexander, Zhen Zhang, Philipp C. Rommel, Nathan Singh, Karl M. Glastad, Max W. Richardson, Keisuke Watanabe, János L. Tanyi, Mark H. O’Hara, Marco Ruella, Simon F. Lacey, Edmund K. Moon, Stephen J. Schuster, Steven Μ. Albelda, Lewis L. Lanier, Regina M. Young, Shelley L. Berger, Carl H. June - Cell 2021 cited by 417

  9. Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma

    Authors: Michael R. Bishop, Michael Dickinson, Duncan Purtill, Pere Barba, Armando Santoro, Nada Hamad, Koji Kato, Anna Sureda, Richard Greil, Catherine Thieblemont, Franck Morschhauser, Martin Janz, Ian W. Flinn, Werner Rabitsch, Yok‐Lam Kwong, Marie José Kersten, Monique C. Minnema, Harald Holte, Esther Hian Li Chan, Joaquín Martínez‐López, Antonia Müller, Richard T. Maziarz, Joseph P. McGuirk, Emmanuel Bachy, Steven Le Gouill, Martin Dreyling, Hideo Harigae, David A. Bond, Charalambos Andreadis, Peter A. McSweeney, Mohamed A. Kharfan‐Dabaja, Simon Newsome, Evgeny Degtyarev, Rakesh Awasthi, Christopher del Corral, Giovanna Andreola, Aisha Masood, Stephen J. Schuster, Ulrich Jäger, Peter Borchmann, Jason R. Westin - New England Journal of Medicine 2021 cited by 520

  10. Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy

    Authors: Melody Smith, Anqi Dai, Guido Ghilardi, Kimberly V. Amelsberg, Sean M. Devlin, Raymone Pajarillo, John Slingerland, Silvia Beghi, Pamela S. Herrera, Paul A. Giardina, Annelie Clurman, Emmanuel Agyemang Dwomoh, Gabriel K. Armijo, Antonio L. C. Gomes, Eric R. Littmann, Jonas Schlüter, Emily Fontana, Ying Taur, Jae H. Park, Maria Lia Palomba, Elizabeth Halton, Josel D. Ruiz, Tania Jain, Martina Pennisi, Aishat Olaide Afuye, Miguel‐Angel Perales, Craig W. Freyer, Alfred L. Garfall, Shannon Gier, Sunita D. Nasta, Daniel J. Landsburg, James N. Gerson, Jakub Svoboda, Justin R. Cross, Elise A. Chong, Sergio Giralt, Saar Gill, Isabelle Rivière, David L. Porter, Stephen J. Schuster, Michel Sadelain, Noelle V. Frey, Renier J. Brentjens, Carl H. June, Eric G. Pamer, Jonathan U. Peled, Andrea Facciabene, Marcel R.M. van den Brink, Marco Ruella - Nature Medicine 2022 cited by 309

  11. Single-Agent Mosunetuzumab Shows Durable Complete Responses in Patients With Relapsed or Refractory B-Cell Lymphomas: Phase I Dose-Escalation Study

    Authors: Lihua E. Budde, Sarit Assouline, Laurie H. Sehn, Stephen J. Schuster, Sung-Soo Yoon, Dok Hyun Yoon, Matthew J. Matasar, Francesc Bosch, Won Seog Kim, Loretta J. Nastoupil, Ian W. Flinn, Mazyar Shadman, Catherine Diefenbach, Carol O'Hear, Huang Huang, Antonia Kwan, Chi-Chung Li, Emily C. Piccione, Michael C. Wei, Shen Yin, Nancy L. Bartlett - Journal of Clinical Oncology 2021 cited by 290

  12. Five-Year Outcomes for Refractory B-Cell Lymphomas with CAR T-Cell Therapy

    Authors: Elise A. Chong, Marco Ruella, Stephen J. Schuster - New England Journal of Medicine 2021 cited by 332

  13. Lisocabtagene maraleucel in chronic lymphocytic leukaemia and small lymphocytic lymphoma (TRANSCEND CLL 004): a multicentre, open-label, single-arm, phase 1–2 study

    Authors: Tanya Siddiqi, David G. Maloney, Saad S. Kenderian, Danielle M. Brander, Kathleen Dorritie, Jacob D. Soumerai, Peter A. Riedell, Nirav N. Shah, Rajneesh Nath, Bita Fakhri, Deborah M. Stephens, Shuo Ma, Tatyana Feldman, Scott R. Solomon, Stephen J. Schuster, Serena Perna, Sherilyn A. Tuazon, San-San Ou, Eniko Papp, Leanne Peiser, Yizhe Chen, William G. Wierda - The Lancet 2023 cited by 198

  14. Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study

    Authors: Anthony R. Mato, Nirav N. Shah, Wojciech Jurczak, Chan Y. Cheah, John M. Pagel, Jennifer A. Woyach, Bita Fakhri, Toby A. Eyre, Nicole Lamanna, Manish R. Patel, Alvaro J. Alencar, Ewa Lech‐Marańda, William G. Wierda, Catherine C. Coombs, James N. Gerson, Paolo Ghia, Steven Le Gouill, David Lewis, Suchitra Sundaram, Jonathon B. Cohen, Ian W. Flinn, Constantine S. Tam, Minal Barve, Bryone J. Kuss, Justin Taylor, Omar Abdel‐Wahab, Stephen J. Schuster, M. Lia Palomba, Katharine L. Lewis, Lindsey E. Roeker, Matthew S. Davids, Xuan Tan, Timothy S. Fenske, Johan Wallin, Donald E. Tsai, Nora Ku, Edward Y. Zhu, Jessica Chen, Ming Yin, Binoj C. Nair, Kevin Ebata, Narasimha Marella, Jennifer R. Brown, Michael Wang - The Lancet 2021 cited by 454

  15. Pembrolizumab for B-cell lymphomas relapsing after or refractory to CD19-directed CAR T-cell therapy

    Authors: Elise A. Chong, Cécile Alanio, Jakub Svoboda, Sunita D. Nasta, Daniel J. Landsburg, Simon F. Lacey, Marco Ruella, Siddharth Bhattacharyya, E. John Wherry, Stephen J. Schuster - Blood 2021 cited by 191

  16. Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia

    Authors: John C. Byrd, Jennifer R. Brown, Susan O’Brien, Jacqueline C. Barrientos, Neil E. Kay, Nishitha Reddy, Steven Coutré, Constantine S. Tam, Stephen P. Mulligan, Ulrich Jaeger, Steve Devereux, Paul M. Barr, Richard R. Furman, Thomas J. Kipps, Florence Cymbalista, Christopher Pocock, Patrick Thornton, Federico Caligaris‐Cappio, Tadeusz Robak, Julio Delgado, Stephen J. Schuster, Marco Montillo, Anna Schuh, Sven de Vos, Devinder Gill, Adrian Bloor, Claire Dearden, Carol Moreno, Jeffrey J. Jones, Alvina D. Chu, Maria Fardis, Jesse McGreivy, Fong Clow, Danelle F. James, Peter Hillmen - New England Journal of Medicine 2014 cited by 1,617

  17. PD-1 blockade modulates chimeric antigen receptor (CAR)–modified T cells: refueling the CAR

    Authors: Elise A. Chong, J. Joseph Melenhorst, Simon F. Lacey, David E Ambrose, Vanessa Gonzalez, Bruce L. Levine, Carl H. June, Stephen J. Schuster - Blood 2016 cited by 497

  18. Persistence of long-lived plasma cells and humoral immunity in individuals responding to CD19-directed CAR T-cell therapy

    Authors: Vijay Bhoj, Dimitrios C. Arhontoulis, Gerald Wertheim, James Capobianchi, Colleen Callahan, Christoph T. Ellebrecht, Amrom E. Obstfeld, Simon F. Lacey, J. Joseph Melenhorst, Farzana Nazimuddin, Wei‐Ting Hwang, Shannon L. Maude, Mariusz A. Wasik, Adam Bagg, Stephen J. Schuster, Michael D. Feldman, David L. Porter, Stephen Grupp, Carl H. June, Michael C. Milone - Blood 2016 cited by 271

  19. Efficacy and safety of CD19‐directed CAR‐T cell therapies in patients with relapsed/refractory aggressive B‐cell lymphomas: Observations from the JULIET, ZUMA‐1, and TRANSCEND trials

    Authors: Jason R. Westin, Marie José Kersten, Gilles Salles, Jeremy S. Abramson, Stephen J. Schuster, Frederick L. Locke, Charalambos Andreadis - American Journal of Hematology 2021 cited by 198

  20. Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study

    Authors: Alexander M. Lesokhin, Stephen M. Ansell, Philippe Armand, Emma Scott, Ahmad Halwani, Martin Gutierrez, Michael Millenson, Adam D. Cohen, Stephen J. Schuster, Daniel Lebovic, Madhav V. Dhodapkar, David Avigan, Bjoern Chapuy, Azra H. Ligon, Gordon J. Freeman, Scott J. Rodig, Deepika Cattry, Lili Zhu, Joseph F. Grosso, M. Brigid Garelik, Margaret A. Shipp, Ivan Borrello, John M. Timmerman - Journal of Clinical Oncology 2016 cited by 1,011

  21. Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis

    Authors: Anthony R. Mato, Chadhi Nabhan, Meghan C. Thompson, Nicole Lamanna, Danielle M. Brander, Brian T. Hill, Christina Howlett, Alan P Skarbnik, Bruce D. Cheson, Clive S. Zent, Jeffrey J. Pu, Pavel Kiselev, André Goy, David F. Claxton, Krista M. Isaac, Kaitlin Kennard, Colleen Timlin, Daniel J. Landsburg, Allison Winter, Sunita D. Nasta, Spencer Henick Bachow, Stephen J. Schuster, Colleen Dorsey, Jakub Svoboda, Paul M. Barr, Chaitra S. Ujjani - Haematologica 2018 cited by 452

  22. Modulation of BCL-2 in Both T Cells and Tumor Cells to Enhance Chimeric Antigen Receptor T-cell Immunotherapy against Cancer

    Authors: Yong Gu Lee, Puneeth Guruprasad, Guido Ghilardi, Raymone Pajarillo, C Sauter, Ruchi P. Patel, Hatcher J. Ballard, Seok Jae Hong, Inkook Chun, Nicholas Yang, Kimberly V. Amelsberg, Katherine D. Cummins, Jakub Svoboda, Saar Gill, Elise A. Chong, Khrystyna North, S. Church, Joseph A. Fraietta, Wan-Jung Chang, Simon F. Lacey, Xueqing Maggie Lu, Yunlin Zhang, Kanupriya Whig, D. Schultz, Sara Cherry, James N. Gerson, Stephen J. Schuster, Patrizia Porazzi, Marco Ruella - Cancer Discovery 2022 cited by 98

  23. Mosunetuzumab monotherapy is active and tolerable in patients with relapsed/refractory diffuse large B-cell lymphoma

    Authors: Nancy L. Bartlett, Sarit Assouline, Pratyush Giri, Stephen J. Schuster, Chan Y. Cheah, Matthew J. Matasar, Gareth P. Gregory, Dok Hyun Yoon, Mazyar Shadman, Keith Fay, Sung‐Soo Yoon, Carlos Panizo, Ian W. Flinn, Anna Johnston, Francesc Bosch, Laurie H. Sehn, Michael C. Wei, Shen Yin, Iris To, Chi‐Chung Li, Huang Huang, Antonia Kwan, Elicia Penuel, Lihua E. Budde - Blood Advances 2023 cited by 93

  24. Bendamustine is safe and effective for lymphodepletion before tisagenlecleucel in patients with refractory or relapsed large B-cell lymphomas

    Authors: Guido Ghilardi, Elise A. Chong, Jakub Svoboda, Philipp Wohlfarth, Sunita D. Nasta, Staci Williamson, J.D. Landsburg, James N. Gerson, Stefan K. Barta, Raymone Pajarillo, Jessie Myers, A.I. Chen, Levanto Schachter, Rebecca Yelton, Hatcher J. Ballard, Alexandria Hodges Dwinal, Shannon Gier, Danielle Victoriano, Erin L. Weber, Ellen Napier, Alfred L. Garfall, David L. Porter, Ulrich Jäger, Richard T. Maziarz, Marco Ruella, Stephen J. Schuster - Annals of Oncology 2022 cited by 97